ALVO vs AMGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: AMGN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALVO and AMGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALVO and AMGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Alvotech develops and manufactures biosimilars, which are approved copies of biologic medicines whose patents have run out, and then hands the selling to partners rather than building its own sales force. Teva covers the United States, Advanz Pharma covers Europe, the UK, Switzerland, Canada and Australia, Dr. Reddy's carries denosumab and is co-developing a Keytruda biosimilar, and Sandoz picked up Canadian and ANZ rights in early 2026. Five biosimilars now produce revenue: adalimumab, ustekinumab, golimumab, aflibercept and denosumab. Money arrives in two very different shapes, product supply to those partners and lumpy licensing and milestone payments, which is why half-year comparisons swing hard. First-half 2026 revenue was about $211.9 million, split almost evenly between roughly $105.9 million of product and $105.7 million of licensing, against $306.1 million a year earlier when milestones happened to land in the period.

Full ALVO guide

Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Its portfolio spans inflammation, oncology, cardiovascular disease, bone health, and rare diseases, with well-known products that have included Enbrel, Prolia and Xgeva, Repatha, Otezla, and a growing pipeline. Amgen pioneered large-scale recombinant-protein and antibody manufacturing and is a leader in biosimilars as older biologics lose patent protection. The 2023 acquisition of Horizon Therapeutics added rare-disease drugs such as Tepezza and Krystexxa. Amgen is also developing obesity and metabolic candidates, including investigational drugs in the GLP-1 class of weight-loss therapies. Headquartered in Thousand Oaks, California, and founded in 1980, Amgen is a member of the Dow Jones Industrial Average and returns substantial cash to shareholders through a growing dividend and buybacks.

Full AMGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALVO drivers: Three FDA decisions in one December week; Five products already generating cash.
• AMGN drivers: Rare disease and Horizon assets; Obesity and metabolic pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Leverage is the dominant risk: roughly $1.31 billion of borrowings against $142.8 million of cash mid-year, a net-debt-to-adjusted-EBITDA ratio above 9x at the end of 2025, and a new term loan carrying 12.50% cash interest maturing December 2027. For AMGN, amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALVO if you believe its drivers more; AMGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALVO and AMGN guides.

ALVO. Adding roughly $1.3 billion of net debt to a $2.1 billion market cap puts enterprise value near $3.4 billion, about 17 times the midpoint of 2026 adjusted EBITDA guidance and roughly 3 times guided revenue. Those multiples only hold if the second half arrives as guided, because the first half produced about a quarter of the full-year EBITDA target. The shares have traded between $2.94 and $9.25 over the past year, a range that says more about how the market prices the regulatory outcome than about the operating business.

AMGN. Amgen trades at a moderate multiple typical of a mature large-cap biopharma, reflecting steady cash flow and a meaningful dividend balanced against patent-cliff and drug-pricing risk. The valuation embeds expectations for the rare-disease and obesity pipelines to offset declines in older franchises. All figures are approximate and move with the share price and reported results; verify current numbers before relying on them.

Headline figures (approximate, September 2026): ALVO shows revenue (ttm) ~$495 million, 2026 revenue guidance ~$650M to $700M, adjusted ebitda (h1 2026) ~$46.9 million, net loss (ttm) ~$180 million; AMGN shows revenue (ttm) ~$33-35 billion (approximate, verify), operating margin ~30%+ (approximate, verify), p/e (ttm) ~20-25x (GAAP varies; approximate, verify), dividend yield ~3% (approximate, verify).

ALVO and AMGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALVO and AMGN exposure against your real portfolio. It is not an investment adviser.